ATE368041T1 - Neue pyrrolderivate als pharmazeutische mittel - Google Patents

Neue pyrrolderivate als pharmazeutische mittel

Info

Publication number: ATE368041T1
Authority: AT; Austria
Prior art keywords: pharmaceutical agents; pyrrole derivatives; new pyrrole; new; derivatives
Prior art date: 2001-05-24

Application number

AT02744115T

Other languages

English (en)

Inventor

Jason Sawyer

Douglas Beight

Paola Ciapetti

Todd Decollo

Alexander Godfrey

Theodore Goodson

David Herron

Hong-Yu Li

Junkai Liao

William Mcmillen

Shawn Miller

Nicolas Mort

Jonathan Yingling

Edward Smith

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-24

Filing date

2002-05-13

Publication date

2007-08-15

2002-05-13 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE368041T1 publication Critical patent/ATE368041T1/de

Links

KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
239000008177 pharmaceutical agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Virology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)

AT02744115T 2001-05-24 2002-05-13 Neue pyrrolderivate als pharmazeutische mittel ATE368041T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29346401P	2001-05-24	2001-05-24

Publications (1)

Publication Number	Publication Date
ATE368041T1 true ATE368041T1 (de)	2007-08-15

Family

ID=23129192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02744115T ATE368041T1 (de)	2001-05-24	2002-05-13	Neue pyrrolderivate als pharmazeutische mittel

Country Status (37)

Country	Link
US (1)	US7087626B2 (de)
EP (1)	EP1397364B1 (de)
JP (2)	JP4519407B2 (de)
KR (1)	KR100861630B1 (de)
CN (2)	CN1269820C (de)
AR (1)	AR036034A1 (de)
AT (1)	ATE368041T1 (de)
AU (1)	AU2002339268B2 (de)
BR (1)	BR0209939A (de)
CA (1)	CA2446820C (de)
CO (1)	CO5540282A2 (de)
CY (1)	CY1106871T1 (de)
CZ (1)	CZ303808B6 (de)
DE (1)	DE60221392T2 (de)
DK (1)	DK1397364T3 (de)
DZ (1)	DZ3506A1 (de)
EA (1)	EA007782B1 (de)
EC (1)	ECSP034859A (de)
EG (1)	EG25614A (de)
ES (1)	ES2289116T3 (de)
HR (1)	HRP20030961B1 (de)
HU (1)	HU228844B1 (de)
IL (2)	IL158512A0 (de)
MX (1)	MXPA03010630A (de)
MY (1)	MY134586A (de)
NO (1)	NO326701B1 (de)
NZ (1)	NZ528525A (de)
PE (1)	PE20030117A1 (de)
PL (1)	PL221339B1 (de)
PT (1)	PT1397364E (de)
SI (1)	SI1397364T1 (de)
SK (1)	SK287857B6 (de)
SV (1)	SV2003001054A (de)
TW (1)	TWI329644B (de)
UA (1)	UA76461C2 (de)
WO (1)	WO2002094833A1 (de)
ZA (1)	ZA200308546B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1397364T1 (sl) *	2001-05-24	2007-12-31	Lilly Co Eli	Novi pirolni derivati kot farmacevtske uäśinkovine
WO2003050120A1 (en) *	2001-12-11	2003-06-19	Smithkline Beecham Corporation	Pyrazolo-pyridine derivatives as antiherpes agents
WO2004026871A1 (en) *	2002-09-17	2004-04-01	Eli Lilly And Company	Novel pyrazolopyridine derivatves as pharmaceutical agents
EP1567528A1 (de) *	2002-11-21	2005-08-31	Eli Lilly And Company	Modulatoren von gemischten lineage kinase
WO2004048381A2 (en) *	2002-11-22	2004-06-10	Eli Lilly And Company	Pyrazoloazepine compounds as pharmaceutical agents
UA80571C2 (en)	2002-11-22	2007-10-10	Lilly Co Eli	Quinolinyl-pyrrolopyrazoles
US7405299B2 (en)	2002-11-27	2008-07-29	Eli Lilly And Company	Compounds as pharmaceutical agents
CL2004000234A1 (es) *	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7511065B2 (en)	2003-11-12	2009-03-31	Eli Lilly And Company	Mixed lineage kinase modulators
US7368445B2 (en)	2004-03-01	2008-05-06	Eli Lilly And Company	Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
TW200639163A (en)	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
WO2006103120A2 (en) *	2005-04-01	2006-10-05	Insa Rouen	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
CA2616196C (en) *	2005-07-22	2012-08-21	Eli Lilly And Company	A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
WO2007021966A1 (en) *	2005-08-12	2007-02-22	Synta Pharmaceuticals Corp.	Pyrazole compounds that modulate hsp90 activity
WO2007076127A2 (en) *	2005-12-22	2007-07-05	Biogen Idec Ma Inc	Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
DE102005061840A1 (de)	2005-12-23	2007-06-28	Merck Patent Gmbh	Triazolderivate
US8034834B2 (en)	2006-05-25	2011-10-11	Synta Pharmaceuticals Corp.	Method for treating proliferative disorders with HSP90 inhibitors
CN101553254A (zh)	2006-10-03	2009-10-07	建新公司	TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009076440A2 (en) *	2007-12-12	2009-06-18	E.I. Du Pont De Nemours And Company	Fungicidal bicyclic pyrazoles
ES2422263T3 (es) *	2008-12-19	2013-09-10	Nerviano Medical Sciences Srl	Pirazoles bicíclicos como inhibidores de la proteinquinasa
US20100267731A1 (en) *	2009-04-17	2010-10-21	Summa Health Systems, LLC	Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
AR081810A1 (es) *	2010-04-07	2012-10-24	Bayer Cropscience Ag	Piridinilpirazoles biciclicos
US9205086B2 (en)	2010-04-19	2015-12-08	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2402339A1 (de) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
EP2402340A1 (de)	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
EP2402338A1 (de)	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
EP2401915A1 (de)	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
EP2402337A1 (de) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
US8871744B2 (en)	2010-07-21	2014-10-28	B & G Partyers, LLC	Compounds and methods for selectively targeting tumor-associated mucins
WO2012138945A1 (en)	2011-04-08	2012-10-11	Aestus Therapeutics, Inc.	Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
US9468612B2 (en)	2011-10-26	2016-10-18	Seattle Children's Hospital	Cysteamine in the treatment of fibrotic disease
AU2012332424A1 (en)	2011-11-02	2014-06-05	Synta Pharmaceuticals Corp.	Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
US9782452B2 (en)	2011-11-22	2017-10-10	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
CN105007939B (zh)	2012-10-05	2018-10-19	卡德门企业有限公司	人抗vegfr-2/kdr抗体
TWI443096B (zh)	2012-12-18	2014-07-01	Ind Tech Res Inst	３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
US9879004B2 (en) *	2013-02-07	2018-01-30	Merck Patent Gmbh	Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
BR112015023261A2 (pt)	2013-03-14	2017-07-18	Massachusetts Inst Technology	composições e métodos para expansão e cultura de células-tronco epiteliais
US8975417B2 (en) *	2013-05-27	2015-03-10	Novartis Ag	Pyrazolopyrrolidine derivatives and their use in the treatment of disease
DK3102576T3 (da)	2014-02-03	2019-07-22	Vitae Pharmaceuticals Llc	Dihydropyrrolopyridininhibitorer af ror-gamma
CN107073042A (zh)	2014-09-03	2017-08-18	布里格海姆妇女医院公司	用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
JO3336B1 (ar)	2014-10-07	2019-03-13	Lilly Co Eli	مركبات أمينو بيريديلوكسي بيرازول
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3277673B1 (de)	2015-04-01	2022-05-04	Rigel Pharmaceuticals, Inc.	Tgf-beta inhibitoren
JP6980534B2 (ja)	2015-06-25	2021-12-15	ザチルドレンズメディカルセンターコーポレーション	造血幹細胞の増大、富化、および維持に関する方法および組成物
EP3331876B1 (de)	2015-08-05	2020-10-07	Vitae Pharmaceuticals, LLC	Modulatoren von ror-gamma
EP3868750A1 (de) *	2015-11-20	2021-08-25	Vitae Pharmaceuticals, LLC	Modulatoren von ror-gamma
CA3010610A1 (en)	2016-01-08	2017-07-13	The Brigham And Women's Hospital, Inc.	Production of differentiated enteroendocrine cells and insulin producing cells
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
WO2017161001A1 (en)	2016-03-15	2017-09-21	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
ES2787449T3 (es) *	2016-06-13	2020-10-16	Genfleet Therapeutics Shanghai Inc	Compuesto de alfa y beta-amida insaturada derivado de benzotriazol usado como inhibidor de TGF-betaRI
US11466003B2 (en)	2016-07-29	2022-10-11	Shanghai Yingli Pharmaceutical Co., Ltd	Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
AU2017386417B2 (en)	2016-12-30	2022-07-14	Frequency Therapeutics, Inc.	1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3618829B1 (de) *	2017-05-05	2023-06-07	Arcus Biosciences, Inc.	Chinazolin-pyridin-derivate zur behandlung von krebsbedingten erkrankungen
CN115716826A (zh)	2017-07-24	2023-02-28	生命医药有限责任公司	RORγ的抑制剂
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
ES2927715T3 (es)	2017-10-05	2022-11-10	Fulcrum Therapeutics Inc	Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
WO2019072942A1 (en)	2017-10-11	2019-04-18	F. Hoffmann-La Roche Ag	BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
JP2021035911A (ja) *	2017-11-15	2021-03-04	大日本住友製薬株式会社	縮環ピラゾール誘導体及びその医薬用途
ES2960412T3 (es)	2017-12-13	2024-03-04	Genfleet Therapeutics Shanghai Inc	Forma cristalina y forma salina del inhibidor de TGF-?RI y método de preparación de las mismas
CN110066276B (zh)	2018-01-24	2020-09-18	上海璎黎药业有限公司	芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CN110066277B (zh)	2018-01-24	2021-07-23	上海璎黎药业有限公司	芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
ES3038913T3 (en)	2018-03-20	2025-10-15	Icahn School Med Mount Sinai	Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20210254006A1 (en)	2018-06-06	2021-08-19	Ideaya Biosciences, Inc.	Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
EP3827010B1 (de) *	2018-07-23	2025-08-27	Brise Pharmaceuticals Co., Ltd.	Bisphosphonat-wirkstoff-konjugate
WO2020037326A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating jag-1
KR102126576B1 (ko)	2018-09-19	2020-06-24	주식회사 대웅제약	4-메톡시 피롤 유도체의 제조 방법
CN112839946B (zh) *	2018-10-31	2022-04-12	江苏奥赛康药业有限公司	作为TGF-βR1激酶抑制剂的双环吡唑类化合物
JP7466128B2 (ja) *	2018-11-22	2024-04-12	フンダシオインスティテュートデレセルカビオメディカ（アイアールビーバルセロナ）	ＴＧＦβ阻害剤およびプロドラッグ
SG11202103457PA (en)	2018-12-27	2021-05-28	Nexys Therapeutics Inc	(pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
CA3124700A1 (en)	2018-12-31	2020-07-09	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
JP7575952B2 (ja)	2019-01-08	2024-10-30	杏林製薬株式会社	１５－ｐｇｄｈ阻害薬
KR102740196B1 (ko) *	2019-01-24	2024-12-10	지앙수 아오사이캉 파마수티칼 씨오., 엘티디.	TGF-β R1 키나아제 억제제로서의 5-(4-피리딜옥시)피라졸 화합물
WO2020160151A1 (en) *	2019-01-31	2020-08-06	Kyorin Pharmaceutical Co., Ltd.	15-pgdh inhibitors
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
CN113557236B (zh) *	2019-06-10	2022-05-10	中国科学院广州生物医药与健康研究院	一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN115052663B (zh)	2020-01-08	2026-06-09	辛瑟斯治疗股份有限公司	Alk5抑制剂缀合物及其用途
WO2022017208A1 (zh) *	2020-07-23	2022-01-27	江苏奥赛康药业有限公司	作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
US12668593B2 (en)	2020-09-28	2026-06-30	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Pyrazole compound and preparation method therefor and use thereof
CN114437082B (zh) *	2020-11-06	2025-04-04	江苏先声药业有限公司	喹啉类化合物
CN115703750B (zh) *	2021-08-17	2024-07-02	黑龙江华瑞生物科技有限公司	一种1-氨基-4-甲基哌嗪的提取纯化方法
CN114249742B (zh) *	2021-11-22	2022-11-01	郑州大学	一种光气探针、荧光书写检测笔及其在光气检测中的应用
CN115969801B (zh) *	2023-03-21	2023-08-25	劲方医药科技(上海)有限公司	用于癌症的药物组合物及其制备方法
WO2024258967A1 (en)	2023-06-13	2024-12-19	Synthis Therapeutics, Inc.	Anti-cd5 antibodies and their uses
GB202309553D0 (en)	2023-06-24	2023-08-09	Ucl Business Ltd	Compostions and uses thereof
CN118652155B (zh) *	2024-06-17	2026-02-27	南京工业大学	一种二芳基乙炔的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5356897A (en) *	1991-09-09	1994-10-18	Fujisawa Pharmaceutical Co., Ltd.	3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
JPH07507796A (ja) *	1992-06-17	1995-08-31	ファルマシア・アンド・アップジョン・カンパニー	抗−アテローム性動脈硬化剤および抗−高コレステロール血症剤として有用なピリジノ−，ピロリジノ−，およびアゼピノ−置換オキシム類
GB9303993D0 (en) *	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
US5565460A (en) *	1993-07-27	1996-10-15	Kyowa Hakko Koygo Co., Ltd.	Therapeutic purine agents for parkinson's disease
US5358947A (en) *	1993-09-13	1994-10-25	American Cyanamid Company	Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
AUPN419395A0 (en) *	1995-07-17	1995-08-10	Treescope Development Co. Pty. Ltd.	Plant protector
FR2746306B1 (fr) *	1996-03-22	1998-04-30	Oreal	Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture
NZ501112A (en)	1997-05-22	2002-10-25	G	Substituted pyrazoles as p38 kinase inhibitors
FR2772379B1 (fr) *	1997-12-16	2000-02-11	Oreal	Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles
GB9809869D0 (en)	1998-05-09	1998-07-08	Medical Res Council	Inhibition of protein kinases
AU2319100A (en)	1999-01-28	2000-08-18	Nippon Shinyaku Co. Ltd.	Amide derivatives and drug compositions
AU4798000A (en)	1999-04-09	2000-11-14	Smithkline Beecham Corporation	Triarylimidazoles
ATE267830T1 (de) *	1999-08-27	2004-06-15	Abbott Lab	Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CA2425288A1 (en) *	2000-10-11	2002-05-02	Sander G. Mills	Pyrrolidine modulators of ccr5 chemokine receptor activity
ATE291020T1 (de)	2001-02-02	2005-04-15	Smithkline Beecham Corp	Pyrazolderivate gegen tgf überexprimierung
SI1397364T1 (sl) *	2001-05-24	2007-12-31	Lilly Co Eli	Novi pirolni derivati kot farmacevtske uäśinkovine
PL1633912T3 (pl) *	2003-05-28	2014-11-28	Oerlikon Textile Gmbh & Co Kg	Sposób oraz urządzenie do układania włókien wykorzystujące technikę igłowania powietrzem
JP4882198B2 (ja)	2003-09-25	2012-02-22	日産自動車株式会社	燃料電池システム

2002
- 2002-05-13 SI SI200230626T patent/SI1397364T1/sl unknown
- 2002-05-13 KR KR1020037015226A patent/KR100861630B1/ko not_active Expired - Fee Related
- 2002-05-13 IL IL15851202A patent/IL158512A0/xx unknown
- 2002-05-13 ES ES02744115T patent/ES2289116T3/es not_active Expired - Lifetime
- 2002-05-13 DK DK02744115T patent/DK1397364T3/da active
- 2002-05-13 PL PL367199A patent/PL221339B1/pl unknown
- 2002-05-13 BR BR0209939-0A patent/BR0209939A/pt not_active Application Discontinuation
- 2002-05-13 DE DE60221392T patent/DE60221392T2/de not_active Expired - Lifetime
- 2002-05-13 CZ CZ20033128A patent/CZ303808B6/cs not_active IP Right Cessation
- 2002-05-13 NZ NZ528525A patent/NZ528525A/en not_active IP Right Cessation
- 2002-05-13 AU AU2002339268A patent/AU2002339268B2/en not_active Ceased
- 2002-05-13 EA EA200301289A patent/EA007782B1/ru not_active IP Right Cessation
- 2002-05-13 CA CA2446820A patent/CA2446820C/en not_active Expired - Fee Related
- 2002-05-13 EP EP02744115A patent/EP1397364B1/de not_active Expired - Lifetime
- 2002-05-13 HU HU0400451A patent/HU228844B1/hu not_active IP Right Cessation
- 2002-05-13 WO PCT/US2002/011884 patent/WO2002094833A1/en not_active Ceased
- 2002-05-13 CN CNB028105087A patent/CN1269820C/zh not_active Expired - Fee Related
- 2002-05-13 JP JP2002591506A patent/JP4519407B2/ja not_active Expired - Fee Related
- 2002-05-13 UA UA20031110606A patent/UA76461C2/uk unknown
- 2002-05-13 MX MXPA03010630A patent/MXPA03010630A/es active IP Right Grant
- 2002-05-13 CN CNA2006100946748A patent/CN1951939A/zh active Pending
- 2002-05-13 HR HR20030961A patent/HRP20030961B1/xx not_active IP Right Cessation
- 2002-05-13 US US10/477,111 patent/US7087626B2/en not_active Expired - Fee Related
- 2002-05-13 AT AT02744115T patent/ATE368041T1/de active
- 2002-05-13 PT PT02744115T patent/PT1397364E/pt unknown
- 2002-05-13 SK SK1416-2003A patent/SK287857B6/sk not_active IP Right Cessation
- 2002-05-15 DZ DZ023506A patent/DZ3506A1/fr active
- 2002-05-22 EG EG2002050542A patent/EG25614A/xx active
- 2002-05-24 SV SV2002001054A patent/SV2003001054A/es unknown
- 2002-05-24 PE PE2002000435A patent/PE20030117A1/es not_active Application Discontinuation
- 2002-05-24 MY MYPI20021941A patent/MY134586A/en unknown
- 2002-05-24 TW TW091111082A patent/TWI329644B/zh not_active IP Right Cessation
- 2002-05-27 AR ARP020101974A patent/AR036034A1/es not_active Application Discontinuation
2003
- 2003-10-20 IL IL158512A patent/IL158512A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA2003/08546A patent/ZA200308546B/en unknown
- 2003-11-18 CO CO03101666A patent/CO5540282A2/es active IP Right Grant
- 2003-11-21 EC EC2003004859A patent/ECSP034859A/es unknown
- 2003-11-21 NO NO20035193A patent/NO326701B1/no not_active IP Right Cessation
2007
- 2007-09-17 CY CY20071101193T patent/CY1106871T1/el unknown
2009
- 2009-04-27 JP JP2009108167A patent/JP2009197016A/ja active Pending

Also Published As

Publication number	Publication date
PT1397364E (pt)	2007-10-22
AR036034A1 (es)	2004-08-04
US7087626B2 (en)	2006-08-08
DZ3506A1 (fr)	2002-11-28
KR100861630B1 (ko)	2008-10-07
MXPA03010630A (es)	2004-03-09
EA200301289A1 (ru)	2004-06-24
ES2289116T3 (es)	2008-02-01
HUP0400451A3 (en)	2008-08-28
US20040106604A1 (en)	2004-06-03
ECSP034859A (es)	2004-01-28
PE20030117A1 (es)	2003-02-12
DE60221392D1 (de)	2007-09-06
NO20035193D0 (no)	2003-11-21
DE60221392T2 (de)	2008-04-17
EP1397364B1 (de)	2007-07-25
IL158512A (en)	2009-07-20
SI1397364T1 (sl)	2007-12-31
CO5540282A2 (es)	2005-07-29
NO20035193L (no)	2003-11-21
EA007782B1 (ru)	2007-02-27
CZ303808B6 (cs)	2013-05-09
PL221339B1 (pl)	2016-03-31
NO326701B1 (no)	2009-02-02
CZ20033128A3 (cs)	2004-06-16
JP2004535404A (ja)	2004-11-25
BR0209939A (pt)	2004-03-30
EG25614A (en)	2012-03-22
SK14162003A3 (en)	2004-11-03
KR20030097895A (ko)	2003-12-31
HU228844B1 (en)	2013-06-28
HRP20030961A2 (en)	2005-08-31
PL367199A1 (en)	2005-02-21
HUP0400451A2 (hu)	2004-12-28
UA76461C2 (en)	2006-08-15
DK1397364T3 (da)	2007-11-26
CA2446820A1 (en)	2002-11-28
CY1106871T1 (el)	2012-09-26
ZA200308546B (en)	2005-04-26
TWI329644B (en)	2010-09-01
SV2003001054A (es)	2003-03-18
MY134586A (en)	2007-12-31
NZ528525A (en)	2005-10-28
EP1397364A1 (de)	2004-03-17
AU2002339268B2 (en)	2007-05-31
CA2446820C (en)	2010-07-13
IL158512A0 (en)	2004-05-12
WO2002094833A1 (en)	2002-11-28
JP2009197016A (ja)	2009-09-03
CN1951939A (zh)	2007-04-25
SK287857B6 (sk)	2012-01-04
CN1269820C (zh)	2006-08-16
JP4519407B2 (ja)	2010-08-04
HRP20030961B1 (en)	2012-01-31
CN1511157A (zh)	2004-07-07
HK1064375A1 (en)	2005-01-28

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1397364

Country of ref document: EP

Publication	Publication Date	Title
DE60221392D1 (de)	2007-09-06	Neue pyrrolderivate als pharmazeutische mittel
ATE279961T1 (de)	2004-11-15	Neue pharmazeutische zusammensetzung
DE60142197D1 (de)	2010-07-01	Pharmazeutische Zusammensetzung
DE60213592D1 (de)	2006-09-14	Flüssige pharmazeutische zusammensetzung
NO20033556D0 (no)	2003-08-11	Farmasöytiske preparater
ATE293590T1 (de)	2005-05-15	Bicyclische aminosäuren als pharmazeutische mittel
FI20011478L (fi)	2003-01-06	Farmaseuttinen koostumus
PL367180A1 (pl)	2005-02-21	Trwała kompozycja farmaceutyczna
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
NO20003968L (no)	2001-07-27	Farmasöytiske preparater
ATE407134T1 (de)	2008-09-15	Triazolyltropanderivate als ccr5-modulatoren
DE50202178D1 (de)	2005-03-10	Neue sulfonat-substituierte pyrazolopyridinderivate
ATE420084T1 (de)	2009-01-15	Neue imidazolderivate und deren verwendung als pharmazeutische mittel
ATE338033T1 (de)	2006-09-15	Thiophen- und thiazolsulfonamide als antineoplastische mittel
NO20035315D0 (no)	2003-11-28	Farmasöytiske kombinasjoner
FI20022128A7 (fi)	2003-06-06	Farmaseuttinen koostumus
ATE366128T1 (de)	2007-07-15	Pharmazeutische zusammensetzung
DE60217390D1 (de)	2007-02-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60201463D1 (de)	2004-11-11	Indanon-Derivate als Duftstoffe
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
ATE287708T1 (de)	2005-02-15	1-amino-alkylcyclohexanederivate als trypanocide mittel
DE10107261B4 (de)	2005-03-10	Pharmazeutische Zusammensetzung
FI5468U1 (fi)	2002-07-30	Farmaseuttinen koostumus
EP1095026A4 (de)	2001-10-31	Pharmazeutische mittel